⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14343220 | 0.67 | — | — | |
| SCHEMBL9469650 | 0.57 | — | — | |
| SCHEMBL737291 | 0.55 | — | — | |
| SCHEMBL2101403 | 0.52 | — | — | |
| SCHEMBL102954 | 0.45 | — | — | |
| SCHEMBL23908691 | 0.41 | — | — | |
| Methenamine SCHEMBL1357153 | 0.38 | KDM4E (0.31) | — | |
| Ammonia Solution, Strong SCHEMBL6782155 | 0.38 | — | — | |
| SCHEMBL25407819 | 0.31 | — | — | |
| SCHEMBL21351608 | 0.31 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024125600-A1 | HETEROCYCLIC COMPOUNDS ACTING AS KRAS INHIBITORS, PREPARATION THEREFOR AND THERAPEUTIC USE THEREOF | 上海科州药物研发有限公司 | 2024-06-20 | — | — | WO | claimed |
| WO-2024092185-A1 | ACYL SULFONAMIDE COMPOUNDS AS INHIBITORS OF POLYOMAVIRUS | VIA NOVA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | claimed |
| WO-2024051812-A1 | AMIDE COMPOUND, AND COMPOSITION AND USE THEREOF | 先声再明医药有限公司 | 2024-03-14 | — | — | WO | claimed |
| WO-2024046370-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITORS, AND PREPARATION AND THERAPEUTIC USE THEREOF | 上海科州药物研发有限公司 | 2024-03-07 | — | — | WO | claimed |
| EP-4320125-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2024-02-14 | — | — | EP | claimed |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | claimed |
| US-20240018140-A1 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-01-18 | — | — | US | claimed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | claimed |
| EP-4213843-A2 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-07-26 | — | — | EP | claimed |
| WO-2023078463-A1 | AZOBENZENE COMPOUND AND APPLICATION THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-11 | — | — | WO | claimed |
| US-7091216-B2 | Substituted furo[2,3-b]pyridine derivatives | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | claimed |
| EP-1249451-B1 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | PFIZER PROD INC (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1558252-A4 | SUBSTITUTED FURO 2,3-B| PYRIDINE DERIVATIVES | MERCK & CO INC (US) | 2006-05-17 | — | — | EP | claimed |
| JP-2005538120-A | — | — | 2005-12-15 | — | — | JP | claimed |
| US-20050272763-A1 | Substituted furo[2,3-b]pyridine derivatives | MERCK SHARP & DOHME CORP. | 2005-12-08 | — | — | US | claimed |
| US-6927220-B2 | Antiproliferative and antitumor agents | PFIZER INC (US) | 2005-08-09 | — | — | US | claimed |
| EP-1558252-A2 | SUBSTITUTED FURO 2,3-B] PYRIDINE DERIVATIVES | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| WO-2004012671-A2 | SUBSTITUTED FURO [2,3-B] PYRIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2004-02-12 | — | — | WO | claimed |
| US-20030045535-A1 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | PFIZER INC. | 2003-03-06 | — | — | US | claimed |
| EP-1249451-A2 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | Pfizer Products Inc. (US) | 2002-10-16 | — | — | EP | claimed |